amfAR & Cytodyn December 1, 2020: “Using lero
Post# of 148278
(Total Views: 554)
Posted On: 07/27/2024 11:25:43 AM
amfAR & Cytodyn December 1, 2020:
“Using leronlimab to pharmacologically copy a CCR5-deficient donor for HIV cure is an exciting next step in our journey towards a cure for the 38 million people living with HIV,” stated Kevin Robert Frost, Chief Executive Officer at amfAR. “While a stem cell transplant is unlikely to be rolled out as an HIV cure, demonstrating that leronlimab can functionally phenocopy CCR5 deficiency and replicate the London and Berlin patients would be a major advancement.”
“Using leronlimab to pharmacologically copy a CCR5-deficient donor for HIV cure is an exciting next step in our journey towards a cure for the 38 million people living with HIV,” stated Kevin Robert Frost, Chief Executive Officer at amfAR. “While a stem cell transplant is unlikely to be rolled out as an HIV cure, demonstrating that leronlimab can functionally phenocopy CCR5 deficiency and replicate the London and Berlin patients would be a major advancement.”
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼